Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of fosaprepitant to currently available antiemtic
treatments of carboplatin chemotherapy-induced nausea and vomiting in advanced non-small cell
lung cancer patients. Half of the patients will receive fosaprepitant in their first
chemotherapy cycle, and a placebo on their second chemotherapy cycle. The other half of the
patients will begin their first chemotherapy cycle.